(RU0214071) Regorafenib Dose Optimization Study (ReDOS); A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer (mCRC)
Description: 
Evaluate the proportion of patients in each arm who complete 2 cycles of treatment and who intend to initiate cycle 3 if no progression is noted on the planned 8-week scan.
Study Number: 

I 264514

Phase: 
2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02368886

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.